BTG-1675A(BTG-1675A) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

其他疾病

在研适应症-

非在研适应症

焦虑症抑郁症

原研机构

BTG International Ltd.

在研机构-

非在研机构

BTG International Ltd.

Abiogen Pharma SpA

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H15NO3

InChIKeyFGCXTWWWHFWHEA-UHFFFAOYSA-N

CAS号812639-72-8

关联

100 项与 BTG-1675A 相关的临床结果

登录后查看更多信息

100 项与 BTG-1675A 相关的转化医学

登录后查看更多信息

100 项与 BTG-1675A 相关的专利（医药）

登录后查看更多信息

1

项与 BTG-1675A 相关的文献（医药）

2016-12-01·European review for medical and pharmacological sciences

The anxiolitic effects of BTG1640 and BTG1675A on ultrasonic isolation calls and locomotor activity of rat pups.

Article

作者: Caprio, M ; Tattoli, M ; Damian, S ; Cagiano, R ; Haragus, H ; Boia, E ; Niculescu, M ; Vermesan, D

OBJECTIVEThe aim of the present study was to evaluate the anxiolytic properties of the new isoxazoline compounds BTG1640 and BTG1675A in comparison with diazepam.MATERIALS AND METHODSWe evaluated the ultrasonic distress emission in both sexes of neonatal rat pups (which seems to be a sensitive indicator of the rat emotional reactivity and represents a valuable tool to screen compounds with expected anxiolytic properties) and the locomotor activity in 30-day old rat pups.RESULTSWe found a significant reduction in the number of emitted ultrasonic calls only after i.p. administration of diazepam 1 mg/kg, while no significant reduction have been detected after i.p. administration of BTG 1640 and BTG 1675A. Furthermore, we found a significant reduction of locomotor activity in the first 10' of the test, only in the group treated with diazepam 0.1 mg.CONCLUSIONSThe tests validating the supposed anxiolytic properties of the new isoxazoline compounds BTG1640 and BTG1675A, in comparison with diazepam, gave negative results.

100 项与 BTG-1675A 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
焦虑症	临床1期	-	BTG International Ltd.	-
焦虑症	临床1期	-	Abiogen Pharma SpA	-
抑郁症	临床1期	-	BTG International Ltd.	-
抑郁症	临床1期	-	Abiogen Pharma SpA	-